Compare TG Therapeutics Inc (TGTX) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Thomson Reuters Corp — how do they compare? TG Therapeutics Inc trades at $49.44 (market cap $7.64B), while Thomson Reuters Corp trades at $104.52 (market cap $45.38B). The key difference: Thomson Reuters Corp is far larger — about 5.9× TG Therapeutics Inc's market cap, and Thomson Reuters Corp pays a 2.5% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TRI | |
|---|---|---|
Market Cap | $7.64B | $45.38B |
Sector | Health | Industrials |
52-Week High | $59.06 | $178.77 |
52-Week Low | $26.94 | $76.55 |
Enterprise Value | $7.84B | $48.00B |
Dividend Yield | — | 2.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Thomson Reuters (TRI) trades at $102.61, down 1.68% today, with a bullish technical signal and strong fundamentals. The company reported Q2 2026 EPS of $0.99, beating estimates, and raised full-year revenue guidance. Valuation ratios include a P/E of 27.61 and a net income margin of 21.22%. Recent news highlights AI-driven growth and a joint venture with KKR.
Outlook is positive with analyst consensus favoring a Buy rating and a $102.33 price target. Key opportunities include recurring revenue growth and AI adoption, while risks involve execution of strategic initiatives and competitive pressures in the legal and tax sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
